Stocks
Funds
Screener
Sectors
Watchlists
ICPT

ICPT - Intercept Pharmaceuticals Inc Stock Price, Fair Value and News

$19.00 
Market Closed

ICPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICPT Price Action

ICPT RSI Chart

ICPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ICPT Valuation

ICPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ICPT Fundamentals

ICPT Revenue

ICPT Earnings

ICPT Profitability

ICPT Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023294.5M306.5M317.7M0
2022262.6M266.2M277.1M285.7M
2021297.3M288.3M275.4M260.8M
2020272.4M283.4M300.9M312.7M
2019196.1M218.8M233.8M252.0M
2018145.9M158.6M164.2M179.8M
201745.6M70.9M107.1M131.0M
20161.8M6.9M11.6M25.0M
20152.8M2.8M2.8M2.8M
20141.6M1.7M1.7M1.7M
20132.1M1.7M1.6M1.6M
20122.6M2.9M2.8M2.4M
20110001.8M
ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
 CEO
 WEBSITEinterceptpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES341